GlassScriptPhysician profile
Adrienne E Wasserman
NPI 1386945905
$6,045.08
in general payments reported to CMS, 2019-2025
47 companies · $1,506 in 2025
The $1,506 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $988 · 2022: $768 · 2023: $1,181 · 2024: $1,602 · 2025: $1,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,806 · Education: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,806.31 |
| Education | $482.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $602.04 | 2021-2025 | Reblozyl, Pomalyst, Opdivo |
| Abbvie INC. | $578.24 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $456.87 | 2021-2023 | Imbruvica, Epkinly |
| Incyte Corporation | $422.35 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
| Seagen INC. | $400.89 | 2021-2023 | Adcetris, Tukysa, Tivdak |
| Janssen Biotech, INC. | $369.29 | 2022-2025 | Erleada, Darzalex, Rybrevant |
| Novartis Pharmaceuticals Corporation | $294.29 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $281.16 | 2021-2025 | Calquence, Enhertu, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $220.60 | 2021-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $194.98 | 2021-2024 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $153.77 | 2021-2024 | Jemperli, Zejula |
| Genzyme Corporation | $136.23 | 2023-2024 | |
| Epizyme, INC. | $129.79 | 2021 | |
| Pfizer INC. | $120.47 | 2023-2025 | |
| Amgen INC. | $111.49 | 2021-2023 | Kyprolis |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adrienne Wasserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.